Vardenafil in patients with erectile dysfunction: achieving treatment optimization

Area of Science:

• Urology
• Pharmacology
• Clinical Trials

Background:

• Erectile dysfunction (ED) affects a significant population of men.
• Vardenafil is a phosphodiesterase type 5 inhibitor used for ED treatment.
• Understanding the learning curve and optimal dosing strategy for vardenafil is crucial for patient outcomes.

Purpose of the Study:

• To determine the number of attempts required for successful sexual intercourse in men with ED using vardenafil.
• To analyze the cumulative probability of achieving and maintaining an erection sufficient for intercourse with vardenafil.
• To compare the efficacy of different vardenafil doses (5, 10, 20 mg) versus placebo based on the number of attempts.

Main Methods:

• Post hoc analysis of a multicenter, randomized, double-blind study.
• Data from men with ED treated with vardenafil (5, 10, 20 mg) or placebo.
• Evaluation of cumulative success rates for penetration and erection maintenance across multiple attempts.

Main Results:

• Vardenafil significantly increased the probability of successful penetration and erection maintenance compared to placebo, especially by the third attempt.
• Cumulative success probabilities for penetration by the third attempt were 82% (5mg), 88% (10mg), and 85% (20mg) vs. 68% (placebo).
• Cumulative probabilities for maintaining an erection by the third attempt were 66% (5mg), 81% (10mg), and 77% (20mg) vs. 53% (placebo).

Conclusions:

• Success rates for erectile dysfunction treatment with vardenafil improve with successive attempts.
• Patients experiencing initial lack of success should consider continuing treatment or dose escalation.
• A plateau in efficacy is observed around the fourth attempt, suggesting optimal treatment strategies involve multiple tries or dose adjustments.